Skip to content
Vildagliptin
Eucreas, Galvus, Icandra, Jalra, Xiliarx, Zomarist (vildagliptin) is a small molecule pharmaceutical. Vildagliptin was first approved as Galvus on 2007-09-25. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10B: Blood glucose lowering drugs, excl. insulins
A10BD: Combinations of oral blood glucose lowering drugs
A10BD08: Metformin and vildagliptin
A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
A10BH02: Vildagliptin
HCPCS
No data
Clinical
Clinical Trials
162 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E116571465130
Diabetes mellitusD003920EFO_0000400E08-E132114
Renal insufficiencyD051437HP_0000083N1911214
Myocardial ischemiaD017202EFO_1001375I20-I2522
HypoglycemiaD007003HP_0001943E16.222
Oxidative stressD018384EFO_100190522
HypertensionD006973EFO_0000537I1011
ExerciseD015444EFO_000048311
Metabolic syndromeD024821EFO_0000195E88.8111
Cognitive dysfunctionD060825G31.8411
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients3115
Type 1 diabetes mellitusD003922EFO_0001359E10112
Insulin resistanceD007333EFO_000261411
Prediabetic stateD011236EFO_1001121R73.0311
Retinal neovascularizationD015861H35.05111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Major depressive disorderD003865EFO_0003761F22111
DyslipidemiasD050171HP_000311911
SchizophreniaD012559EFO_0000692F2011
Kidney transplantationD01603011
Glucose intoleranceD018149HP_0000833R73.0311
Gestational diabetesD016640HP_0009800O24.411
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD01381022
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVILDAGLIPTIN
INNvildagliptin
Description
Vildagliptin is an amino acid amide.
Classification
Small molecule
Drug classdipeptidyl aminopeptidase-IV inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2
Identifiers
PDB
CAS-ID274901-16-5
RxCUI596554
ChEMBL IDCHEMBL142703
ChEBI ID
PubChem CID6918537
DrugBankDB04876
UNII IDI6B4B2U96P (ChemIDplus, GSRS)
Target
Agency Approved
DPP4
DPP4
Organism
Homo sapiens
Gene name
DPP4
Gene synonyms
ADCP2, CD26
NCBI Gene ID
Protein name
dipeptidyl peptidase 4
Protein synonyms
ADABP, ADCP-2, Adenosine deaminase complexing protein 2, CD26, Dipeptidyl peptidase IV, dipeptidylpeptidase 4, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2), DPP IV, Gly-Pro naphthylamidase, Post-proline dipeptidyl aminopeptidase IV, T-cell activation antigen CD26, TP103, Xaa-Pro-dipeptidylaminopeptidase
Uniprot ID
Mouse ortholog
Dpp4 (13482)
dipeptidyl peptidase 4 (P28843)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Galvus - Novartis
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,420 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
11,641 adverse events reported
View more details